Lbp Am Sa Purchases Shares of 4,397 Bio-Rad Laboratories, Inc. (NYSE:BIO)

Lbp Am Sa purchased a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 4th quarter, Holdings Channel reports. The firm purchased 4,397 shares of the medical research company’s stock, valued at approximately $1,444,000.

Several other large investors also recently made changes to their positions in the company. Wealthfront Advisers LLC acquired a new stake in shares of Bio-Rad Laboratories in the fourth quarter valued at approximately $342,686,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Bio-Rad Laboratories by 1.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company’s stock valued at $147,583,000 after purchasing an additional 4,260 shares during the period. Westfield Capital Management Co. LP increased its stake in shares of Bio-Rad Laboratories by 3.9% in the third quarter. Westfield Capital Management Co. LP now owns 252,769 shares of the medical research company’s stock valued at $84,571,000 after purchasing an additional 9,584 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Bio-Rad Laboratories in the third quarter valued at approximately $83,681,000. Finally, Mawer Investment Management Ltd. increased its stake in shares of Bio-Rad Laboratories by 63.0% in the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock valued at $72,900,000 after purchasing an additional 84,237 shares during the period. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Up 4.2 %

Bio-Rad Laboratories stock opened at $255.34 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The firm has a market cap of $7.15 billion, a price-to-earnings ratio of -3.93 and a beta of 0.99. Bio-Rad Laboratories, Inc. has a 1 year low of $244.00 and a 1 year high of $387.99. The firm’s 50 day moving average price is $311.97 and its two-hundred day moving average price is $328.01.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. On average, research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Wells Fargo & Company lowered their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Finally, StockNews.com lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $395.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.